Proje Geliştirme ve
Koordinasyon Birimi

2015-11-11 United Kingdom: Diagnostics, Multiplexing Technology, Assay Development, Bespoke Multiplex ELISA, Instrument Development, Validation


 
Diagnostics, Multiplexing Technology, Assay Development, Bespoke Multiplex ELISA, Instrument Development, Validation 

Description of the project offered: 
Aeirtec is an SME with unique multiplexing immunoassay technology and has developed the highest sensitivity marker multiplexing immunoassay (simultaneous ELISA) service so far located in Europe (simultaneous 10-50 marker measurement in small sample volumes at sensitivity below 0.1 pg/ml). (www.aeirtec.com). Aeirtec is also involved in development of in vitro diagnostics. Our activity is applied to both industrial and academic research projects and is also conducted in collaborations incorporating genomic, proteomic and metabolomic biomarker validation studies. The activity is conducted under GLP and ISO 17025 compliance. Aeirtec have already contributed to EU funded projects as a partner and in conduct of outsourced multiplex marker measurement in FP7. Aeirtec also conducts bioinformatic analysis on data generated from the multiplexing enabling bioinformatics integration of physiological, genetic and soluble markers. The multiplexing is fully customisable in choice of marker inclusion. Aeirtec also generate novel assays to novel biomarkers to be included in multiplexes; including protein / antibody conjugation. The activity extends to multiplex measurement of other markers such as microRNA (miRNA). Aeirtec also conducts bioinformatic analysis on data generated from the multiplexing enabling bioinformatics integration of physiological, genetic and soluble markers. Aeirtec is interested in collaboration on multiplex measurement in large (eg epidemiology), small cohort studies, or in vitro experimentation supernatants. Measurement of biomarkers simultaneously in small sample volumes (as low as 10 microlitres) enables measurement of a large number of markers through extensive use of samples for multiple rounds of multiplexing for different marker panels. To date, our expertise has been applied in translational research, drug development, cell therapy for immune, inflammatory disease and regeneration, health / disease mechanism studies and food / nutrition studies. This has included measurement of cytokine, chemokine, adipokine, growth factors, cancer markers, enzymes etc. across CNS, cardiovascular, metabolic, gastrointestinal, respiratory, immune (allergy and autoimmune), inflammatory, oncology, renal, musculoskeletal and infectious diseases (eg sepsis). Aeirtec is interested in contributing to projects within Horizon 2020 either through partner of service provision.
Project proposer:   Stephen KILFEATHER (United Kingdom)
Partner role:  Project participant 
Partner organisation:  Small or medium-sized enterprise (SME)
Call for proposal title:  N/A 


Description of the collaboration sought: 
Aeirtec is an SME with unique multiplexing immunoassay technology and has developed the highest sensitivity marker multiplexing immunoassay (simultaneous ELISA) service so far located in Europe (simultaneous 10-50 marker measurement in small sample volumes at sensitivity below 0.1 pg/ml). (www.aeirtec.com). Aeirtec is also involved in development of in vitro diagnostics. Our activity is applied to both industrial and academic research projects and is also conducted in collaborations incorporating genomic, proteomic and metabolomic biomarker validation studies. The activity is conducted under GLP and ISO 17025 compliance. Aeirtec have already contributed to EU funded projects as a partner and in conduct of outsourced multiplex marker measurement in FP7. Aeirtec also conducts bioinformatic analysis on data generated from the multiplexing enabling bioinformatics integration of physiological, genetic and soluble markers. The multiplexing is fully customisable in choice of marker inclusion. Aeirtec also generate novel assays to novel biomarkers to be included in multiplexes; including protein / antibody conjugation. The activity extends to multiplex measurement of other markers such as microRNA (miRNA). Aeirtec also conducts bioinformatic analysis on data generated from the multiplexing enabling bioinformatics integration of physiological, genetic and soluble markers. Aeirtec is interested in collaboration on multiplex measurement in large (eg epidemiology), small cohort studies, or in vitro experimentation supernatants. Measurement of biomarkers simultaneously in small sample volumes (as low as 10 microlitres) enables measurement of a large number of markers through extensive use of samples for multiple rounds of multiplexing for different marker panels. To date, our expertise has been applied in translational research, drug development, cell therapy for immune, inflammatory disease and regeneration, health / disease mechanism studies and food / nutrition studies. This has included measurement of cytokine, chemokine, adipokine, growth factors, cancer markers, enzymes etc. across CNS, cardiovascular, metabolic, gastrointestinal, respiratory, immune (allergy and autoimmune), inflammatory, oncology, renal, musculoskeletal and infectious diseases (eg sepsis). Aeirtec is interested in contributing to projects within Horizon 2020 either through partner of service provision. 
Expertise sought: Agricultural biotechnology, Resources of the sea. Fisheries, Food, Agriculture, Veterinary and animal sciences, Medical biotechnology, Life sciences, Biotechnology, Medicine. Health, Industrial biotech, Nanotechnology and Nanosciences, 
Roles sought: Project participant, 
Organisation types sought: Research, Industry, Technology transfer, Small or medium-sized enterprise (SME), 
Countries sought: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom,